Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $223
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $249 to $223.
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $249 to $223.